Concord Biotech Limited

NSE CONCORDBIO.NS

Concord Biotech Limited Return on Assets (ROA) for the year ending March 31, 2024: 18.12%

Concord Biotech Limited Return on Assets (ROA) is 18.12% for the year ending March 31, 2024, a 14.24% change year over year. Return on assets measures profitability against assets; higher ROA indicates efficient asset use and profitability.
  • Concord Biotech Limited Return on Assets (ROA) for the year ending March 31, 2023 was 15.86%, a 19.01% change year over year.
  • Concord Biotech Limited Return on Assets (ROA) for the year ending March 31, 2022 was 13.32%, a -32.92% change year over year.
  • Concord Biotech Limited Return on Assets (ROA) for the year ending March 31, 2021 was 19.86%, a 10.47% change year over year.
  • Concord Biotech Limited Return on Assets (ROA) for the year ending March 31, 2020 was 17.98%.
Key data
Date Return on Assets (ROA) Return on Equity (ROE) Return on Capital Employed (ROCE) Interest Coverage Ratio
Market news
SV Wall Street
NSE: CONCORDBIO.NS

Concord Biotech Limited

CEO Mr. Ankur Vaid
IPO Date Aug. 18, 2023
Location India
Headquarters 16th Floor, B-Wing
Employees 1,377
Sector Health Care
Industries
Pharmaceuticals Biotechnology
Description

Concord Biotech Limited, a biopharma company, engages in the research and development, manufacturing, marketing, and sale of pharmaceutical products in India and internationally. It provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. The company also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, and pimecrolimus for immunosuppressants therapeutic segment; temsirolimus, everolimus, romidepsin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment; mupirocin, mupirocin calcium, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, and micafungin sodium for anti-fungal therapeutic segment; and lovastatin and pravastatin sodium for other applications. In addition, it provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.

StockViz Staff

February 6, 2025

Any question? Send us an email